Healthcare
Live Price
Offline$8.07
+6.32% today
1Y Change
-5.45%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Teladoc Health, Inc. (TDOC) is a Healthcare stock with a market cap of $1.17B and listed on NYSE. The stock last traded around $8.07 and down 5.4% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -1.5%, EPS growth of +80.6%, a dividend yield of 0.0%. What stands out right now is revenue -1.5%, EPS +80.6%, free cash flow +0.9% with operating margin -7.6% and ROIC -7.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TDOC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TDOC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TDOC Max Drawdown
-52.75%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TDOC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.0B
-15.5% YoY
FY Net Income
-$428.8M
+96.9% YoY
Free Cash Flow
$185.5M
+7.3% YoY
Revenue Growth
-1.5%
EPS Growth
+80.6%
Gross Margin
65.6%
Net Margin
-6.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.5B | 2.6B | 2.6B | 2.4B | 2.0B |
| Gross Profit | 1.8B | 1.8B | 1.8B | 1.7B | 1.4B |
| Operating Income | -263M | -1.0B | -249M | -13.7B | -266M |
| EBITDA | 147M | 32M | 44M | -8M | -31M |
| Net Income | -200M | -1.0B | -220M | -13.7B | -429M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 781M | 1.3B | 1.1B | 918M | 893M |
| Total Assets | 3.1B | 3.5B | 4.4B | 4.7B | 17.7B |
| Total Liabilities | 1.7B | 2.0B | 2.1B | 2.4B | 1.7B |
| Shareholder Equity | 1.4B | 1.5B | 2.3B | 2.3B | 16.0B |
| Total Debt | 1.0B | 1.6B | 1.6B | 1.6B | 1.3B |
| Net Debt | 259M | 286M | 469M | 669M | 387M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
194M
+2.5% YoY
Capital Expenditures
9M
+48.2% YoY
Free Cash Flow
185M
+7.3% YoY
Key ratios
Gross Margin
65.6%
Operating Margin
-7.6%
Net Margin
-6.8%
ROE
-12.4%
Debt / Equity
0.77x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.